Abstract:Abstract The ER-α36 protein is a 36kDa novel splice variant of the full length 66kDa ER-α. ER-α36 lacks both transcriptional activation domains of ER-α66 but retains the DNA-binding domain and partial dimerization and ligand-binding domains. It has been shown that ER-α36 could trigger membrane-initiated signaling in ER-α36 over-expressing 293 cells, suggesting that ER-α36 might have functions linked with activation of intracellular signaling.To further explore the mechanism(s) of ER-α36 activation of intracellular signaling, in particular the possible relationship between ER-α36 and HER2 in breast cancer, we performed a pilot study. First, we examined the correlation between ER-α36 and HER2 by immunohistochemistry (IHC) using a specific anti-ER-α36 antibody designed against a unique epitope located in the C-tail of ER-a36 which is not present in ER-α66. The results showed that the expression of ER-α36 was highly associated with HER2 in a cohort of 249 breast tumors (P<0.05). Then, we examined whether ER-α36 physically interacts with HER2 in breast cancer cell lines using co-immunoprecipitation (Co-IP) and Western blotting (WB) experiments. We found that ER-α36 interacts with HER2 in both MCF7/HER2 and BT474 cell lines. Second, we explored whether ER-α36 influences the activation of HER2 and its downstream signaling by knocking down ER-α36 expression in both MCF7/HER2 and BT474 cell lines. We found that knockdown of ER-α36 by siRNA abrogated the activation of P-HER2, as well as Akt and MAPK, in both MCF7/HER2 and BT474 cells. Finally, we asked the key question whether ER-α36 was associated with cell proliferation/survival. Strikingly, we found that when both MCF7/HER2 and BT474 cells were deprived of ER-α36 by siRNA, they died quickly, whereas control cells grew normally.In conclusion, our preliminary data suggests that there might be a crosstalk between ER-α36 and HER2 signaling, and that this crosstalk might promote tumor cell survival through HER2/Akt and/or HER2/MAPK signaling pathways in breast cancer. Thus, ER-α36 may be a valuable biomarker and a novel therapeutic target in breast cancer. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 2121.

Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues.

Expression of ERα36 in gastric cancer samples and their matched normal tissues.

Quantitative Profiles of the Mrnas of ER-α and Its Novel Variant ER-α36 in Breast Cancers and Matched Normal Tissues

Estrogen Receptor Beta Variants Mrna Expressions in Gastric Cancer Tissues and Association with Clinicopathologic Parameters

Estrogen Receptor Alpha Variant Er Alpha 46 Mediates Growth Inhibition and Apoptosis of Human Ht-29 Colon Adenocarcinoma Cells in the Presence of 17 Beta-Oestradiol

Prognostic Role of Estrogen Receptor Α and Estrogen Receptor Β in Gastric Cancer

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

ER-alpha36, a Novel Variant of ER-alpha, is Expressed in ER-positive and -Negative Human Breast Carcinomas.

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer.

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

A Variant of Estrogen Receptor-Alpha, Her-Alpha 36: Transduction of Estrogen- and Antiestrogen-Dependent Membrane-Initiated Mitogenic Signaling

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance.

Identification, Cloning, and Expression of Human Estrogen Receptor-Α36, a Novel Variant of Human Estrogen Receptor-Α66

Crosstalk Between Estrogen Receptor Alpha 36, A Dominant Extra-Nuclear Er, And Her2 Promotes Tumor Cell Survival In Breast Cancer

The therapeutic target of estrogen receptor-alpha36 in estrogen-dependent tumors

A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Reduced Alternative Splicing of Estrogen Receptor Alpha in the Endometrium of Women with Endometriosis.

RETRACTED: Predictive and Prognostic Value of ER-α36 Expression in Breast Cancer Patients Treated with Chemotherapy

ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen via HMGA2